# Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $246.81, market value $16.0 billion.

## Valuation
- **P/E (trailing): 16.9×** (5-yr avg 17.2×, 3-yr avg 17.2×). Jazz Pharmaceuticals plc Common Stock (Ireland) trades at 16.9× trailing earnings, close to its own five-year average of 17.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.6×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.5×**. Each dollar of revenue is priced at 3.5×.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 9.9%** (5-yr avg 12.7%). Free cash flow equals 9.9% of the market value, below its five-year average of 12.7%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 5.9%**. The inverse of the P/E: 5.9% of the price is earned each year.

## Profitability
- **Operating margin: 19.5%**. 19.5% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -8.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -8.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 8.6%**. Return on all capital, debt included, is 8.6%.
- **Return on assets: 8.1%**. Each dollar of assets produces 8.1% of profit.

## Growth
- **Revenue growth (1 yr): 4.9%** (3-yr 5.3%/yr, 5-yr 12.5%/yr). Revenue grew 4.9% over the last year, against 12.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -167.5%**. Earnings per share fell 167.5%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 1.4%/yr**. Free cash flow has compounded at 1.4% a year over three years.

## Financial health
- **Debt to equity: 1.24**. Debt is 1.24 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Jazz Pharmaceuticals plc Common Stock (Ireland) does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (20 analysts). 20 analysts cover Jazz Pharmaceuticals plc Common Stock (Ireland); the consensus is buy, with an average price target of $289.45 (+17% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 92.8%** (YTD 45.2%, 3-mo 3.5%). The shares are up 92.8% over twelve months including dividends.
- **From 52-week high: -7.3%** (99.2% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.47** (volatility 37%). Beta of 0.47 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=JAZZ · Page: https://foliofundamentals.com/stocks/jazz

Not investment advice.